DBV Technologies (NASDAQ:DBVT) Stock Jumps 4.9% – Still a Buy?

DBV Technologies S.A. (NASDAQ:DBVT) traded up 4.9% on Monday. The stock traded as high as $12.00 and last traded at $12.13. 281,502 shares traded hands during trading, a decline of 6% from the average session volume of 300,963 shares. The stock had previously closed at $11.56.

Analysts Set New Price Targets

DBVT has been the topic of several recent research reports. Weiss Ratings cut shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Citizens Jmp lifted their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Finally, Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Stock Performance

The stock’s 50-day moving average price is $13.51 and its 200-day moving average price is $16.84. The company has a market capitalization of $734.06 million, a price-to-earnings ratio of -3.36 and a beta of -0.95.

Institutional Trading of DBV Technologies

A number of institutional investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC acquired a new position in shares of DBV Technologies during the 1st quarter worth approximately $21,159,000. Perceptive Advisors LLC acquired a new stake in DBV Technologies during the 1st quarter valued at $20,146,000. Elmind Capital LP acquired a new stake in DBV Technologies during the 1st quarter valued at $5,536,000. Vivo Capital LLC increased its position in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after buying an additional 205,943 shares in the last quarter. Finally, Dorsey Wright & Associates purchased a new position in DBV Technologies during the first quarter worth $2,142,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.